AbbVie Inc. (NYSE:ABBV) is experiencing a positive shift in market sentiment as financial analysts raise their price targets after reporting total net revenues of approximately $15.8 billion, with the immunology segment alone generating $7.9 billion. Morgan Stanley increased its target to $269 from $261, while HSBC upgraded the stock to 'Buy' and set a target of $265, up from $225. Despite a recent downgrade from BofA, AbbVie is still expected to deliver strong earnings of $3.37 per share for the current quarter and reaffirm its commitment to shareholders by raising its quarterly dividend by 5.5%.
“AbbVie · has shares · beaten the S&P 500 · 12.4%”
“AbbVie · trades at · stock price · $229.70”
“AbbVie · has shown free cash flow margin · average · 36.6%”
“AbbVie · has constant currency revenue growth · average over two years · 4.7%”
“AbbVie · trades at forward P/E · 16.7× · $229.70 per share”
“AbbVie Inc. · is represented in · Zacks Investment Research · Free Stock Analysis Report”
“AbbVie Inc. (NYSE:ABBV) · is · one of the best stocks for the next decade”
“Morgan Stanley · raised · the firm’s price target on AbbVie · $269 from $261”
“HSBC · upgraded · AbbVie · to Buy from Hold”
“HSBC · set · a price target for AbbVie · $265, which was up from $225”
“AbbVie · generated · $7.9 billion in revenue from the immunology segment”
“AbbVie Inc. (NYSE:ABBV) · reported · total net revenues · ~$15.8 billion”
.svg&width=160)
